ERCC1 Genotype

Most of what this result tells you only matters if you are ever treated for cancer with a platinum drug like cisplatin or oxaliplatin. It reports a fixed inherited spelling in a gene your cells rely on to fix damaged DNA. In some cancers and some ancestries, that spelling tracks with how well platinum chemotherapy works.

This is a research-grade marker, not a routine clinical test. There are no agreed cutoffs, and a single genotype should never drive a decision by itself. Knowing it early simply gives you and any future care team one more piece of context to weigh.

What This Test Actually Reports

The test reads your inherited version of ERCC1 (excision repair cross-complementation group 1), a gene that helps run one of your cells' cleanup crews for bulky DNA damage, a system scientists call nucleotide excision repair. This same crew removes the DNA damage that platinum chemotherapy deliberately creates, which is why the gene draws so much interest in cancer care.

Two common spelling changes get studied most. One is called rs11615 (also written as codon 118 or C118T), and the other is rs3212986 (also written as C8092A). The rs11615 change is often described as a reason platinum sensitivity might differ, but the evidence for how it affects ERCC1 is mixed. The most rigorous functional study found no difference in ERCC1 production or platinum sensitivity between the two versions of this spelling, and any effect appears modest and may depend on which other nearby variants a person carries. Treat the mechanism as a plausible idea, not an established fact.

One caution runs through this entire field. Your inherited genotype is not the same measurement as the amount of ERCC1 protein a tumor actually produces. Many studies measure tumor ERCC1 expression rather than germline genotype, and the two often do not line up. When evidence below comes from expression rather than your genotype, that is flagged.

Platinum Response in Colorectal Cancer

One frequently cited signal comes from colorectal cancer treated with oxaliplatin plus 5-FU (a common chemotherapy pairing). In a single study of 91 people with advanced colorectal cancer, tumor response rose steadily by genotype at codon 118: about 62 out of 100 people with the T/T version responded, versus roughly 42 out of 100 with C/T and about 21 out of 100 with C/C. This was one small study, though. Larger meta-analyses pooling many trials have not confirmed an overall effect, and the direction even reverses by ancestry, with the T version looking favorable in Caucasian patients but unfavorable in Asian ones.

That same study found no meaningful genotype effect when patients received 5-FU alone or an irinotecan-based regimen. That pattern matters: it suggests the genotype speaks to platinum drugs specifically, not to chemotherapy in general. If your treatment does not include a platinum agent, this result carries little weight.

Platinum Response in Ovarian Cancer

In ovarian cancer, the rs11615 result depends heavily on ancestry. A meta-analysis pooling 10 studies and 1,866 patients found no overall link across all populations, yet a clear association within Asian populations and none in Caucasian populations. A separate Asian-population analysis found people carrying the C-containing versions were several times more likely to respond to platinum than those with T/T (odds ratios around 4.94 for CT versus TT and 6.15 for CC versus TT).

The same Asian analysis found longer overall survival for CC than TT, with TT carrying roughly 70% higher risk of death (hazard ratio 1.71). A smaller cohort of 60 women pointed the same direction for treatment resistance, where C/T and T/T together had about 80% lower odds of platinum resistance (odds ratio 0.17), though survival did not separate.

The picture is not uniform. In one large ovarian cancer trial, codon 118 showed no link to progression or death, while the other variant, C8092A, did: carrying its A version was tied to roughly 44% higher risk of progression and 50% higher risk of death (hazard ratios 1.44 and 1.50). Different variants, different endpoints, different answers.

Cancer Risk Associations

Beyond treatment, ERCC1 spellings have been studied as inherited risk markers, again with results that shift by cancer type and ancestry. A meta-analysis in breast cancer found rs11615 tied to a modest increase in risk, on the order of 14% for carrying the risk allele and about 24% for one common comparison (odds ratios 1.14 and 1.24). A case-control study also reported stronger enrichment of the T/T version in triple-negative breast cancer.

Other cancers tell a more cautionary story. In lung cancer, a large pooled analysis of over 10,000 cases and 13,000 controls first showed a small rs11615 signal, but that association vanished once one influential study was removed. In head and neck cancer, meta-analysis found no significant association for either rs11615 or rs3212986. A gastric cancer study did report increased risk in an Eastern Chinese population.

The takeaway is not a single risk number you should memorize. It is that these are small, inconsistent, ancestry-dependent effects. A risk allele here is a faint statistical nudge, not a diagnosis or a prediction that cancer will occur.

Chemotherapy Side Effects

Some evidence links these variants to how harshly platinum chemotherapy hits healthy tissue. A systematic review connected both rs11615 and rs3212986 to a higher risk of cisplatin-related kidney injury. A lung cancer cohort reported a higher risk of low white blood cell counts (neutropenia) with one rs11615 form, and a broader review tied ERCC1 variation to oxaliplatin-related anemia risk.

These toxicity signals are the most directly useful part of the genotype for someone actively in treatment, because they speak to monitoring and dose decisions rather than to whether you will ever get cancer. They still belong in a conversation with an oncologist, not a self-directed change to a regimen.

Why the Same Variant Can Point Two Ways

It can seem contradictory that a lower-repair version predicts better platinum response in treated patients yet sometimes tracks with worse biology in surgery-only settings. Both can be true because this is not a simple good-number, bad-number marker. It is a repair-capacity indicator, and less repair capacity means platinum damage is harder for a tumor to undo, but it can also let more mutations accumulate over time when no chemotherapy is involved. Ancestry adds another layer, which is why an effect can appear in Asian cohorts and disappear in Caucasian ones. Read the genotype as context that depends on your specific situation, not as a fixed verdict.

A One-Time Result You Revisit Over Time

Because this is a germline genotype, it never changes. You test once, and the result is yours for life. There is nothing to trend and no reason to repeat it unless a lab flags a low-confidence variant call that warrants confirmation by a second method.

The value comes from what you do with it over years, not from retesting. If you are ever diagnosed with a cancer where platinum chemotherapy is on the table, this result is worth bringing to your oncologist. It is one input alongside your tumor type, your ancestry, and other markers, not a standalone answer.

What to Do With an Unexpected Result

If your genotype flags a variant tied to platinum response or toxicity, the next step is interpretation, not action. Pair it with the measurement it does not replace: your tumor's actual ERCC1 expression, a different test entirely, plus your ancestry and companion DNA-repair markers such as XRCC1 that have outperformed ERCC1 alone in some studies. An oncologist or a clinician trained in genetics is the right person to fit these pieces together.

If you carry a risk-associated version and have a strong family history of cancer, a genetic counselor can help you decide whether broader hereditary cancer testing makes sense, since ERCC1 is a narrow single-gene look rather than a full inherited-cancer panel. The right pattern to act on is a combination of findings, not this one number in isolation.

When the Result Can Mislead

• Genotype is not expression: your inherited spelling often does not match how much ERCC1 a tumor actually makes, and several studies found no correlation between the two, so genotype cannot substitute for a tumor expression test.
• Ancestry changes the meaning: some of these variants are common in one population and rare in another, and an effect seen in Asian cohorts may not apply if your ancestry differs.
• Panel coverage is limited: this test reads specific spellings only, so a result that looks reassuring does not rule out other rare ERCC1 changes the assay was never designed to detect.
• Consumer-grade versus clinical-grade differ: a genotype call from a direct-to-consumer report may not carry the same accuracy as a clinical assay, and unexpected findings deserve confirmation.